Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Publications section text was updated to clarify that entries are automatically filled from PubMed and may not pertain to the study; the revision/version label was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedDeletion removes a general government funding/operating-status notice, while the Study Details content (title, conditions, plan, and eligibility) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange Detected- Added a government funding notice and current operating status information, plus a new version tag v3.2.0. - Removed the term 'Adrenal cortex carcinoma' and the older version tag v3.1.0.SummaryDifference2%

- Check78 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the Back to Top link was removed. This shows a version increment and a small UI change.SummaryDifference0.1%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.